Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAF Inhibitory Pathways.

A series of novel 3-cyanopyridone/pyrazoline hybrids () exhibiting dual inhibition against EGFR and BRAF has been developed. The synthesized target compounds were tested in vitro against four cancer cell lines. Compounds and demonstrated remarkable antiproliferative activity, boasting GI values of 27 nM and 25 nM, respectively. These hybrids exhibited dual inhibitory effects on both EGFR and BRAF pathways. Compounds and , akin to Erlotinib, displayed promising anticancer potential. Compound emerged as the most potent inhibitor against cancer cell proliferation and BRAF. Notably, both compounds and induced apoptosis by elevating levels of caspase-3 and -8 and Bax, while downregulating the antiapoptotic Bcl2 protein. Molecular docking studies confirmed the potential of compounds and to act as dual EGFR/BRAF inhibitors. Furthermore, in silico ADMET prediction indicated that most synthesized 3-cyanopyridone/pyrazoline hybrids exhibit low toxicity and minimal adverse effects.